Home
Storia in 1 fonti
Legend interim CEO talks rising competition as Carvykti maker posts first profit
More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's interim CEO Alan Bash discusses competition from T-cell engagers and Gilead's new autologous CAR-T, as the Carvykti maker posted its first profitable quarter.
Raccontata da
fiercepharma.com
Timeline cronologica
- ·
Biopharma saw a Q2 sales boom led by Lilly, Sanofi, Regeneron and Astellas
With all the fretting from the pharmaceutical industry about competition from China, patent protection losses, price reduction initiatives and other government measures with the…
- ·
Legend interim CEO talks rising competition as Carvykti maker posts first profit
More than four years after its CAR-T star Carvykti’s initial FDA approval, Legend Biotech has reached a major milestone, posting its first profitable quarter. | Legend Biotech's…
- ·
Fierce Pharma Asia—Legend’s first profit; Taiho, Cullinan’s EGFR win; WuXi AppTec’s reprieve
As Legend Biotech became profitable, the company is navigating the next phase of growth for its flagship CAR-T therapy, Carvykti. | As Legend Biotech became profitable, the…